CanVirex posesses a highly valuable portfolio of measles virus vectors for cancer immunotherapy and vaccination for protection against COVID-19. The lead candidates for the oncology program (CanVirex01) and the COVID-19 vaccine project are pre-clinically fully developed and initiation of clinical testing is anticipated in 2021.
Along with the strategic research alliance with the Heidelberg University Hospital, CanVirex constantly screens potential vector candidates that can be added to the existing portfolio.
The established biomarker program routinizes testing of molecular signatures and predictive biomarkers. This program will be run in parallel to clinical trials. Identification of biomarkers is essential for providing patient-specific treatment options.